Published on 1 Oct 2024 on GuruFocus.com · via Yahoo Finance
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
On September 24, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) marked a significant portfolio addition by acquiring 3,059,411 shares of Pliant Therapeutics Inc (NASDAQ:PLRX), a notable player in the biopharmaceutical industry. This transaction, executed at a price of $11.33 per share, represents a new holding for the firm, emphasizing its strategic investment in the healthcare sector. The acquisition not only diversifies Paradigm Biocapital's portfolio but also underscores its commitment to investing in companies with groundbreaking medical therapies.
Insight into Paradigm Biocapital Advisors LP (Trades, Portfolio)
Warning! GuruFocus has detected 3 Warning Signs with PLRX.